Table 2.
List of the 42 new reimbursement nomenclature codes [18]
| Domains of clinical pathology | Biological matrices | Names of the nomenclature codes |
|---|---|---|
| Clinical chemistry | Blood | Separated identification and assessment of C22–C26 fatty acids, phytanic acid and pristanic acid by mass spectrometry |
| Methylmalonic acid and succinylacetone assessment | ||
| Pipecolic acid assessment | ||
| Guanidinoacetate and creatine assessment | ||
| Measurement of alpha-d-galactose 1-phosphate (Gal-1-P) in erythrocytes | ||
| Separated assessment of cholestanol, 7-dehydrocholesterol and 8-dehydrocholesterol | ||
| Separated assessment of desmosterol, lathosterol, campesterol, sitosterol and 27-hydroxycholesterol | ||
| Identification of asialotransferrin, monosialotransferrin, and asialotransferrin | ||
| Determination of the Alpha-1-proteinase inhibitor (= alpha-1-antitrypsin) phenotype | ||
| Serum/plasma | Organic acids assessment | |
| Urine | Guanidinoacetate and creatine assessment | |
| Separated assessment of polyols after fractionation | ||
| Separated assessment of mono- and disaccharides after fractionation | ||
| Separated assessment of polyols, monosaccharides and disaccharides after fractionation | ||
| Cerebrospinal fluid | Specific mass spectrometric identification and dosage of organic acids | |
| Specific assessment of amino acids by LC–MS/MS after derivatization and fractionation | ||
| Guanidinoacetate and creatine assessment | ||
| Stool | Measurement of pancreatic Elastase 1 | |
| Amniotic fluid | Separated assessment of 7-dehydrocholesterol and 8-dehydrocholesterol | |
| Hormonology | Blood | Assessment of fibroblast growth factor 23 |
| Assessment of pregnenolone | ||
| Assessment of 17-hydroxypregnenolone | ||
| Proinsulin measurement | ||
| Saliva | Cortisol measurement | |
| Haematology | Blood | Eosin-5′-maleimide (EMA) binding test |
| Coagulation and hemostasis | Plasma | Alpha 2-Antiplasmin measurement |
| Functional analysis of von Willebrand factor-cleaving protease (ADAMTS13) | ||
| Identification of the von Willebrand factor‐cleaving protease inhibitor | ||
| Diagnosis of type 2N von Willebrand disease | ||
| von Willebrand factor collagen-binding activity assay | ||
| von Willebrand factor multimer analysis | ||
| von Willebrand factor propeptide assay | ||
| Detection of heparin-induced antibodies (= diagnosis of heparin induced thrombocytopenia [HIT]) | ||
| Functional analysis of HIT antibodies | ||
| Platelet secretion assay | ||
| Measurement of prekallikrein (Fletcher Factor) anticoagulant activity and of high-molecular-weight kininogen | ||
| Immuno-haematology and non-infectious serology | Serum | Detection of anti-podocytes antibodies in the context of membranous glomerulonephritis diagnosis |
| Detection of anti-podocytes antibodies in the context of membranous glomerulonephritis follow-up | ||
| Determination of anti-acetylcholine receptor antibodies | ||
| Immunoassay identification of autoantibodies against bullous pemphigoid (BP) antigen 180, BP230 (bullous pemphigoid antigen 1), DSG1 (desmoglein 1), DSG3 (desmoglein 3), type VII collagen and envoplakin | ||
| Follow-up of the production of autoantibodies against bullous pemphigoid (BP) antigen 180, BP230 (bullous pemphigoid antigen 1), DSG1 (desmoglein 1), DSG3 (desmoglein 3), type VII collagen and envoplakin by immunoassay |